Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

iSpecimen (ISPC) Gains from Sales and Divestitures (2024 - 2025)

iSpecimen has reported Gains from Sales and Divestitures over the past 2 years, most recently at $400.0 for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures fell 77.78% year-over-year to $400.0; the TTM value through Dec 2025 reached $400.0, down 77.78%, while the annual FY2025 figure was $400.0, 77.78% down from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $400.0 at iSpecimen, up from $382.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $1800.0 in Q4 2024 and troughed at $152.0 in Q1 2025.